SCHEMBL254303

SCHEMBL254303

COC(=O)c1ccc(-c2ccc(N)cc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
HIF1A Q16665 1/20 0.49
KDM4E B2RXH2 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DYRK1A Q13627 1/20 0.46
GPR119 Q8TDV5 1/20 0.43
HPGD P15428 2/20 0.43
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
EGLN1 Q9GZT9 2/20 0.42
NAAA Q02083 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38656583 1.00 MAPK1 (0.57) MAPK1HIF1AKDM4EL3MBTL1DYRK1A
Hydrochloric Acid SCHEMBL6345836 0.98 MAPK1 (0.56) MAPK1HIF1AKDM4EL3MBTL1DYRK1A
SCHEMBL38656189 0.87 MAPK1 (0.57) MAPK1KDM4EL3MBTL1DYRK1AGPR119
SCHEMBL721291 0.86 MAPK1 (0.65) MAPK1KDM4EL3MBTL1DYRK1AHPGD
SCHEMBL31359497 0.86 MAPK1 (0.65) MAPK1KDM4EL3MBTL1DYRK1AHPGD
SCHEMBL7942053 0.86 MAPK1 (0.53) MAPK1HIF1AKDM4EL3MBTL1DYRK1A
SCHEMBL2037294 0.85 MAPK1 (0.59) MAPK1KDM4EL3MBTL1DYRK1AGPR119
SCHEMBL11041168 0.85 MAPK1 (0.59) MAPK1HIF1AKDM4EL3MBTL1DYRK1A
Hydrochloric Acid SCHEMBL14125808 0.84 MAPK1 (0.62) MAPK1KDM4EL3MBTL1DYRK1AHPGD
SCHEMBL5937430 0.83 EGLN1 (0.57) MAPK1KDM4EL3MBTL1DYRK1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612368-B2 Cancer treatments targeting cancer stem cells REMEDY PLAN, INC. (US) 2026-04-28 US disclosed
CN-119930509-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2025-05-06 CN disclosed
CN-114929672-B Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2025-01-21 CN disclosed
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 US disclosed
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 US disclosed
EP-4055008-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS Remedy Plan, Inc. (US) 2022-09-14 EP disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 CN disclosed
WO-2012031298-A2 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612368-B2 Cancer treatments targeting cancer stem cells MALT1, BCOR, MCL1 MAPK1 2918/4885HIF1A 177/4885KDM4E 2964/4885
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 MAPK1 3430/4885HIF1A 366/4885KDM4E 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.